Abeona Names Keith Goldan to Board, Veteran CFO with Two Syndax Approvals
Abeona Therapeutics named Keith A. Goldan to its Board, effective April 1, 2026, and appointed him Audit Committee Chair. Goldan brings over 20 years of financial leadership, including as Syndax’s CFO since 2022—leading two product approvals and commercialization—and CFO roles at Optinose and Fibrocell.
1. Appointment Details
Effective April 1, 2026, Abeona Therapeutics appointed Keith A. Goldan as an independent member of its Board of Directors and Chair of the Audit Committee, strengthening the company’s financial oversight at the board level.
2. Goldan’s Financial Track Record
Goldan has served as Syndax Pharmaceuticals’ CFO since 2022, overseeing two product approvals and commercialization, and previously held CFO positions at Optinose and Fibrocell, as well as finance leadership roles at NuPathe, PuriCore, Biosyn, ViroPharma and KPMG.
3. Strategic and Financial Implications
The new appointment underscores Abeona’s focus on bolstering its strategic and financial capabilities to support ZEVASKYN® commercial production and future gene therapy development, potentially enhancing investor confidence and facilitating capital market transactions.